About Henlius
Company Profile
Corporate Culture
Honor
Board of Directors
Management Team
Advisory Committee
Product
Marketed Products
Products in R&D
Clinical Trial
Science & Technology
R&D Result
Innovation Centre
Technology Platform
Quality Management
Manufacturing
Collaborations
Investor Relations
Information Disclosure
Corporate Governance
Financial Reports
Stock Info
IR Calendar
Investor Presentation
Analyst Coverage
Contact Information
Media
Press Release
Multi-media
Media Reports
Media Enquiry
Careers
Talent Philosophy
Staff Life
Training and Development
Job Opportunities
Contact Us
Contact Information
Customer Message
Privacy
Legal Statement
Compliance
EN
简体
EN
繁體
Home
About Henlius
Company Profile
Corporate Culture
Honor
Board of Directors
Management Team
Advisory Committee
Product
Marketed Products
Products in R&D
Clinical Trial
Science & Technology
R&D Result
Innovation Centre
Technology Platform
Quality Management
Manufacturing
Collaborations
Investor Relations
Information Disclosure
Listing Documents
Announcement & Circulars
Corporate Governance
Financial Reports
Stock Info
IR Calendar
Investor Presentation
Analyst Coverage
Contact Information
Media
Press Release
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
Multi-media
Company
Event
Popular Science
Media Reports
Media Enquiry
Careers
Talent Philosophy
Staff Life
Training and Development
Job Opportunities
Contact Us
Contact Information
Customer Message
Privacy
Legal Statement
Compliance
Be the most trusted biotech company
Press Release
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
Multi-media
Company
Popular Science
Highlights
Download
Media Reports
Media Enquiry
2020-10-05
Investigational New Drug Application of Henlius SARS-CoV-2 Neutralizing Antibody HLX70 Approved by US FDA
2020-09-30
Henlius Granted Exclusive Development and Commercialisation Rights of HLX02 in the US and Canada to Accord
2020-09-30
Mr. Wenjie Zhang Appointed as the CEO of Henlius to Keep Innovating in Operation Management Models and Implementing the Global Strategy
2020-09-20
Henlius Released Phase 3 Study Data of its Bevacizumab Biosimilar HLX04 at CSCO 2020
2020-09-20
First patient dosed in phase 1 clinical trial of Henlius pertuzumab biosimilar HLX11
2020-09-17
Scientific Innovation for the Benefit of the Patients -Exclusive Interview with Henlius Co-CSO and Senior Vice President of R&D, Dr. Ningshu Liu
2020-09-17
The Updated Multi-Centre Phase 3 Clinical Study Data of Trastuzumab 汉曲优® Released in ESMO
2020-09-09
Henlius Bevacizumab Biosimilar Received NDA Acceptance Notification from NMPA
2020-08-14
China's First Trastuzumab Biosimilar 汉曲优® Approved by NMPA
1
...
27
28
29
30
31
32
...
39